Nanoscope Therapeutics has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) for the treatment of Stargardt disease to improve visual function.
Hyloris Pharmaceuticals’ partner AFT Pharmaceuticals (AFT) and Salus Pharmaceuticals have signed an exclusive licensing and distribution agreement for new, dual mode-of-action non-opioid pain treatment Maxigesic IV.
Hikma Pharmaceuticals has signed a new exclusive licensing and commercialisation agreement with Junshi Biosciences for the cancer treatment drug, toripalimab.
Italian Medicines Agency (AIFA) has granted operational authorisation to biotech company ReiThera to open its new production area at its pharmaceutical facility located at the Castel Romano Technopole.
Global biotechnology firm CSL has signed a strategic option and license deal with biopharmaceutical company Translational Sciences for thrombus dissolving drug candidate, TS23.
Shanghai Fosun Pharmaceutical’s member Hangzhou Celregen Therapeutics has entered into an exclusive license agreement with Japanese regenerative medicine start-up Cellusion for CLS001.
Evaxion Biotech, along with UMass Chan Medical School, has received a funding from the US National Institutes of Health (NIH) to develop a lead vaccine candidate to treat gonorrhea.
CARsgen Therapeutics has announced the start of production at its Current Good Manufacturing Practice (CGMP) manufacturing facility in North Carolina, US and released the first CAR T cells batch for clinical trials.
BioDuro-Sundia and X-Chem have collaborated to launch the DNA encoded compound library (DEL) technology services in China for the discovery of new small molecule drugs.
Kiniksa Pharmaceuticals has entered into a global license agreement with Roche and its subsidiary, Genentech, for the development and commercialisation of an investigational fully human monoclonal antibody, vixarelimab.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.